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Kumiko Tanaka1, Taka-Aki Nakada1*, Ryuzo Abe1, Sakae Itoga2, Fumio Nomura2 and Shigeto Oda1Proton pump inhibitors (PPIs) are commonly used in
ICUs. Here, we report a severe case of rhabdomyolysis
associated with omeprazole. A 20-year-old man, who
previously had been healthy, visited a hospital with
epigastric pain. An upper gastrointestinal endoscopy
revealed a duodenal ulcer in an active stage. He was
admitted to the hospital and received intravenous
omeprazole (20 mg) twice a day. On day 14 of admission,
he developed muscular pain, predominantly in the lower
extremities, and had elevated serum creatinine phosphoki-
nase (CPK) (28,314 IU/L; normal is less than 25 IU/L)
(Figure 1). The patient was transferred to the hospital’s
ICU on day 16, since the serum CPK (112,240 IU/L)
and myoglobin (25,082 ng/mL; normal is less than
154 ng/mL) levels were extremely high. After potential
causes of elevated CPK were considered, omeprazole-
associated rhabdomyolysis seemed the most probable
diagnosis. We discontinued intravenous omeprazole
administration and started aggressive fluid repletion,
continuous renal replacement therapy, and urine alka-
lization. The CPK and myoglobin levels successively
decreased and reached within the normal range on day 31.
The patient recovered completely and was discharged on
day 38.
No allergic symptom was detected in this case. The
results of a drug-induced lymphocyte stimulation test
for omeprazole were negative. Altered pharmacokinetics
of omeprazole has been reported in patients with genetic
variations in CYP2C19, which encodes a principal enzyme
to metabolize omeprazole [1]; therefore, we performed
DNA sequencing of the entire coding regions in CYP2C19.
The analysis revealed no serious loss-of-function variations
in the gene (intermediate metabolizer genotype) [1]. The
plasma omeprazole level on day 15 was within normal
range (380 ng/mL; normal is less than 400 ng/mL) [1].
Thus, the metabolism and plasma levels of omeprazole
were not likely to be associated with rhabdomyolysis.* Correspondence: taka.nakada@nifty.com
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unless otherwise stated.PPI-associated rhabdomyolysis is generally rare. This
case had extremely high CPK/myoglobin levels compared
with those reported earlier [2,3]. The mechanism of
PPI-associated rhabdomyolysis has not yet been fully
elucidated. Omeprazole is known to specifically bind
to H+K+-ATPase at the gastric parietal cells. H+K+-ATPase
is present in other tissues, including vascular smooth
muscle cells [4]. Blocking H+K+-ATPase may induce
artery vasoconstriction and ischemia, resulting in PPI-
associated ocular damage [5], suggesting that a pos-
sible mechanism of PPI-associated rhabdomyolysis is via
H+K+-ATPase in other tissues. Omeprazole activates gene
expression of insulin-like growth factor-binding protein-1,
a key mediator for muscle protein synthesis under stress
[6], via the aryl hydrocarbon receptor [7]. The aryl hydro-
carbon receptor pathway may involve PPI-associated
rhabdomyolysis. We need to be aware of the possibilities,
though rare, of rhabdomyolysis associated with omepra-
zole in the ICU.
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Figure 1 Course of serum creatinine phosphokinase and
myoglobin levels and intravenous administration of omeprazole.
CPK, creatinine phosphokinase.
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